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Correction to: British Journal of Cancer 2001; 85 (Suppl 2): 1–5
An error has been noted within Figure 1. The chemotherapy
regimen shown in the ECOG/SWOG/CALGB INT-0101 study is
incorrect and should be six cycles of CAF (cyclophosphamide/
adriamycin/5-ﬂuorouracil) and not six cycles of CMF (cyclophos-
phamide/methotrexate/5-ﬂuorouracil), as presented. The corrected
version of the ﬁgure is shown here.
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Figure 1 Clinical trials designs for studies involved in the evaluation of goserelin as adjuvant treatment in early breast cancer in pre-/perimenopausal
patients.
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